TriangleABCD-NK (NCT06158828)
ABCD-NK trial for Acute Myeloid Leukemia, Pediatric (NCT06158828). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
For high-risk acute myeloid leukemia, a bone marrow transplant is often the best chance, and a parent is usually a half-matched donor. Relapse afterward is the main way it fails.
The idea: give the new immune system a head start with trained natural killer cells from the same donor.
At Washington University in St. Louis, the donor's graft is first stripped of the T cells most likely to cause graft-versus-host disease. A week after transplant, the patient receives natural killer cells from that donor that were briefly exposed to three immune signals in the lab, which gives them a memory-like state: stronger, longer-lasting killers of leukemia. Low-dose interleukin-2 follows.
ABCD-NK is a pilot safety study led by Thomas Pfeiffer. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.